Technical Analysis for CRBU - Caribou Biosciences, Inc.

Grade Last Price % Change Price Change
D 24.05 0.08% 0.02
CRBU closed down 0.87 percent on Monday, September 27, 2021, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical CRBU trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.08%
Wide Bands Range Expansion 0.08%
Inside Day Range Contraction -0.78%
Wide Bands Range Expansion -0.78%
New Uptrend Bullish -9.21%
Lower Bollinger Band Walk Weakness -9.21%
Oversold Stochastic Weakness -9.21%
Lower Bollinger Band Walk Weakness -0.99%
Lower Bollinger Band Touch Weakness -0.99%
Oversold Stochastic Weakness -0.99%
Older End-of-Day Signals for CRBU ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 5 hours ago
60 Minute Opening Range Breakout about 6 hours ago
Down 3% about 7 hours ago
Fell Below Previous Day's Low about 7 hours ago
Down 2 % about 7 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Caribou Biosciences, Inc. Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Biology Cell Therapy Leukemia Multiple Myeloma Hematologic Malignancies Breakthrough Therapy Chimeric Antigen Receptor T Cell CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

Is CRBU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.65
52 Week Low 15.0
Average Volume 921,322
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 26.85
10-Day Moving Average 25.58
Average True Range 2.30
ADX 24.68
+DI 22.10
-DI 22.99
Chandelier Exit (Long, 3 ATRs) 25.76
Chandelier Exit (Short, 3 ATRs) 29.39
Upper Bollinger Bands 31.10
Lower Bollinger Band 22.59
Percent B (%b) 0.17
BandWidth 31.67
MACD Line 0.09
MACD Signal Line 0.83
MACD Histogram -0.7371
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.21
Resistance 3 (R3) 26.13 25.31 25.85
Resistance 2 (R2) 25.31 24.75 25.35 25.73
Resistance 1 (R1) 24.67 24.41 24.99 24.76 25.61
Pivot Point 23.86 23.86 24.02 23.90 23.86
Support 1 (S1) 23.22 23.30 23.54 23.30 22.45
Support 2 (S2) 22.40 22.96 22.44 22.33
Support 3 (S3) 21.76 22.40 22.21
Support 4 (S4) 21.85